Comparative Pharmacology
Head-to-head clinical analysis: KLOXXADO versus REVEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KLOXXADO versus REVEX.
KLOXXADO vs REVEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KLOXXADO (flumazenil) is a benzodiazepine antagonist that competitively inhibits the activity at the benzodiazepine binding site on the GABA-A receptor, thereby reversing the effects of benzodiazepines.
Nalmefene is an opioid antagonist that competitively binds to mu, delta, and kappa opioid receptors, reversing or preventing opioid effects.
5 mg intranasally as a single dose; may repeat once after 2-3 minutes if response inadequate.
0.5 mg to 1 mg intravenous, intramuscular, or subcutaneous, repeated every 2 to 5 minutes as needed, up to a maximum of 2 mg total dose per episode.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1-4 hours); clinical context: short half-life supports rapid reversal of opioid effects but requires monitoring for renarcotization, especially with long-acting opioids.
Terminal elimination half-life: 2.4-4.2 hours in adults; prolonged in renal impairment (up to 50 hours).
Hepatic metabolism primarily via CYP3A4 to inactive metabolites; renal excretion accounts for <1% of unchanged drug; fecal excretion accounts for approximately 50-60% of the dose as metabolites.
Renal: 60% as unchanged drug and metabolites; fecal: 40% via biliary elimination.
Category C
Category C
Opioid Antagonist
Opioid Antagonist